NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET
Company Participants
Matthew Duffy – Chief Business Officer
Jonathan Javitt – Founder, Chairman and Chief Scientist
Richard Narido – Interim Chief Financial Officer and Treasurer
Michael Abrams – Incoming Chief Financial Officer
Conference Call Participants
Jason Kolbert – D. Boral Capital
Ed Woo – Ascendiant
Vernon Bernardino – H.C. Wainwright
Operator
Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Third Quarter 2024 Earnings Conference Call. At this time, all lines are in the listen-only mode. Following the presentation we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Monday, November 18, 2024.
I would now like to turn the conference over to Mr. Matthew Duffy, Chief Business Officer. Please go ahead.
Matthew Duffy
Thank you, Ina, and welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations.
Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements may be made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued last week as well as the Form 10-Q, which may be accessed from the Investors page of the NRx Pharmaceuticals website.
Joining me today on the call are Dr. Jonathan Javitt, our Founder, Chairman and CEO and Chief Scientist; as well as Richard Narido, our Interim Chief
